Form 4: Lisata Therapeutics Director Heidi Henson Reports Stock Transactions

Director Heidi Henson reports acquisition of restricted stock units and adjustments to beneficial ownership in Lisata Therapeutics.

Summary

• On January 9, 2025, Heidi Henson, a director of Lisata Therapeutics, acquired 15,789 restricted stock units (RSUs) under the company's 2018 Equity Incentive Compensation Plan.
• These RSUs will vest on January 9, 2026.
• Following the reported transaction, Henson beneficially owns 55,269 shares of common stock, including 15,789 unvested RSUs.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, suggesting stability and alignment of interests. It's a neutral to slightly positive indicator.

Positives

• The grant of restricted stock units aligns the director's interests with the long-term performance of the company.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure related to equity compensation for a company director, common in the biopharmaceutical industry to incentivize management and align their interests with shareholders.

Comparison to Industry Standards

• Equity compensation is a standard practice in the biopharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely grant stock options and restricted stock units to their executives and directors.
• The vesting schedule of one year is relatively standard.

Stakeholder Impact

• The grant of RSUs could have a slightly dilutive effect on existing shareholders.
• The vesting of RSUs incentivizes the director to work towards increasing shareholder value.

Key Dates